Plasmodium falciparum resistance to artemisinin derivatives in southeast Asia threatens malaria control and elimination activities worldwide. To monitor the spread of artemisinin resistance, a molecular marker is urgently needed. Here, using whole-genome sequencing of an artemisinin-resistant parasite line from Africa and clinical parasite isolates from Cambodia, we associate mutations in the PF3D7_1343700 kelch propeller domain ('K13-propeller') with artemisinin resistance in vitro and in vivo. Mutant K13-propeller alleles cluster in Cambodian provinces where resistance is prevalent, and the increasing frequency of a dominant mutant K13-propeller allele correlates with the recent spread of resistance in western Cambodia. Strong correlations between the presence of a mutant allele, in vitro parasite survival rates and in vivo parasite clearance rates indicate that K13-propeller mutations are important determinants of artemisinin resistance. K13-propeller polymorphism constitutes a useful molecular marker for large-scale surveillance efforts to contain artemisinin resistance in the Greater Mekong Subregion and prevent its global spread.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007947PMC
http://dx.doi.org/10.1038/nature12876DOI Listing

Publication Analysis

Top Keywords

artemisinin resistance
16
molecular marker
12
plasmodium falciparum
8
mutant k13-propeller
8
resistance
7
artemisinin
5
marker artemisinin-resistant
4
artemisinin-resistant plasmodium
4
falciparum malaria
4
malaria plasmodium
4

Similar Publications

Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei.

Int J Parasitol Drugs Drug Resist

December 2024

W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD, 21210, USA. Electronic address:

Fosmidomycin and clindamycin target the Plasmodium apicoplast. Combination clinical trials have produced mixed results with the primary problem being the recrudescent infection frequency by day 28. Given that antibiotic efficacy against bacterial infections often depends on the constant drug presence over several days, we hypothesized that the antimalarial blood or liver stage efficacy of fosmidomycin and clindamycin could be improved by implementing a more frequent dosing schedule.

View Article and Find Full Text PDF

Increasing reports of chloroquine resistance (CQR) in Plasmodium vivax endemic regions have led to several countries, including Indonesia, to adopt dihydroarteminsin-piperaquine instead. However, the molecular drivers of CQR remain unclear. Using a genome-wide approach, we perform a genomic analysis of 1534 P.

View Article and Find Full Text PDF

Inaccurate communication in health sciences: The case of 'partial artemisinin resistance' for the treatment of malaria.

New Microbes New Infect

December 2024

Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Location AMC, Amsterdam Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, the Netherlands.

Background: Accurate scientific terminology is crucial in health sciences to avoid misinterpretations. The use of 'artemisinin resistance' to describe delayed parasite clearance may be inaccurately equated with full resistance, as is typically the case when 'resistance' is used with other pathogens, leading to potential confusion. In 2018, the World Health Organization (WHO) introduced 'partial artemisinin resistance' to more accurately reflect the delayed parasite clearance observed with artemisinin-based therapies.

View Article and Find Full Text PDF

Background: Novel antimalarials are needed to address emerging resistance to artemisinin and partner drugs. We did two trials to evaluate safety, tolerability, pharmacokinetics, and activity against blood stage Plasmodium falciparum for the drug candidate MMV533.

Methods: A phase 1a first-in-human (FIH) trial was conducted at Nucleus Network (Melbourne, VIC, Australia).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!